BIIB Biogen Inc.
Price Chart
Executive Summary
Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4 per share in contingent value rights, adding two commercial products (EMPAVELI and SYFOVRE) that generated $689 million in combined 2025 net product revenue. The deal is expected to be accretive to Biogen's non-GAAP EPS in 2027 and materially increase its non-GAAP EPS CAGR through the end of the decade, while expanding Biogen into nephrology ahead of a key Phase 3 readout for felzartamab in 2027.
Key Financial Metrics
Actionable Insight
The acquisition transforms Biogen's near-term growth profile with two approved products and a pipeline catalyst in nephrology. Monitor Q2 2026 earnings for updated financial guidance incorporating Apellis, and track SYFOVRE sales trajectory for CVR payout potential. The deal removes Apellis overhang and provides a clear revenue growth driver beyond Biogen's legacy neurology franchise.
Key Facts
- Biogen acquired Apellis for $41 per share in cash plus up to $4 per share in CVRs tied to SYFOVRE sales thresholds.
- Approximately 105.7 million shares (82.4% of outstanding) were tendered; remaining shares converted at the same price.
- EMPAVELI and SYFOVRE generated $689 million in combined net product revenue in 2025.
- The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and materially increase non-GAAP EPS CAGR through the end of the decade.
- Apellis brings established nephrology commercial infrastructure to support felzartamab launch, with first Phase 3 readout in antibody-mediated rejection expected in H1 2027.
Financial Impact
Total consideration of approximately $4.3 billion in cash plus up to $420 million in CVRs based on 105.7M shares tendered at $41/share plus $4/share CVR; combined acquired products had $689M in 2025 revenue.
Risk Factors
- Integration risk: realizing expected synergies and maintaining Apellis product sales momentum.
- SYFOVRE faces competition from Iveric Bio's avacincaptad pegol (Izervay) in geographic atrophy.
- CVR payments depend on achieving SYFOVRE net sales thresholds, which may not be met.
- Felzartamab Phase 3 readout in 2027 is binary and may not succeed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294955 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
today
|
ANALYST-UPGRADE
| $182.61 awaiting T+5 | awaiting T+5 | — | $187.80 (+2.84%) |
|
May 14, 2026
6d ago
|
ANALYST-UPGRADE
| $178.76 $185.18 | ▲ +3.59% | ▲ +2.20% | $187.80 (+5.06%) |
|
May 14, 2026
6d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
May 14, 2026
6d ago
|
8-K
| — | awaiting T+5 | — | — |
|
May 14, 2026
6d ago
|
Press Release
| $204.58 awaiting T+5 | awaiting T+5 | — | $187.80 (−8.20%) |
|
May 8, 2026
12d ago
|
Press Release
| $192.75 $191.37 | ▲ +0.71% | ▲ +2.18% | $187.80 (+2.57%) |
|
May 1, 2026
19d ago
|
ANALYST-UPGRADE
| $156.63 $164.13 | ▲ +4.79% | ▲ +4.49% | $187.80 (+19.90%) |
|
Apr 28, 2026
22d ago
|
DEFA14A
| — | awaiting T+5 | — | — |
|
Apr 22, 2026
28d ago
|
ANALYST-UPGRADE
| $190.12 $190.39 | ▲ +0.14% | ▲ +0.09% | $187.80 (−1.22%) |
|
Apr 20, 2026
4w ago
|
ANALYST-UPGRADE
| $183.33 $180.56 | ▼ −1.51% | ▼ −2.42% | $187.80 (+2.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access